Education
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
ALGS Stock Chart & Stats
$9.86
-$2.78(-6.79%)
At close: 4:00 PM EST
$9.86
-$2.78(-6.79%)
Day’s Range― - ―
52-Week Range$3.76 - $46.80
Previous CloseN/A
Volume178.18K
Average Volume (3M)86.97K
Market Cap
$44.35M
Enterprise Value-$41.55M
Total Cash (Recent Filing)$99.10M
Total Debt (Recent Filing)$6.07M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Mar 05, 2026EPS Estimate
-2.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding5,351,374
10 Day Avg. Volume122,947
30 Day Avg. Volume86,969
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.61
Price to Sales (P/S)63.27
P/FCF Ratio-3.09
Enterprise Value/Market Cap-0.94
Enterprise Value/Revenue-15.70
Enterprise Value/Gross Profit-17.40
Enterprise Value/Ebitda0.49
Forecast
1Y Price Target
$112.50Price Target Upside1040.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentALG-055009’s strong Phase 2a efficacy, favorable safety, and combination potential with incretins continue to draw partnering interest amid MASH M&A activity.
Regulatory EndorsementsRegulators have endorsed HBV DNA suppression below the lower limit of quantitation as an approvable chronic suppression monotherapy endpoint, providing a clear path to registration.
Strategic PositioningAligos remains well positioned to extend its leadership in liver disease innovation with a solid cash position, validating presentations, and multiple inflection points ahead.
Bears Say
Clinical Development RisksRisks include clinical development risk for ALG-000184, particularly if future studies show safety concerns, resistance, or diminished biomarker effects.
Financing RisksFinancing risk given Aligos’ cash runway into 2H26, and the potential for additional equity issuance to support Phase 2b and Phase 3 activities.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
Aligos Therapeutics lowest stock price was $3.76 and its highest was $46.80 in the past 12 months.
What is Aligos Therapeutics’s market cap?
Aligos Therapeutics’s market cap is $44.35M.
When is Aligos Therapeutics’s upcoming earnings report date?
Aligos Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 98 days.
How were Aligos Therapeutics’s earnings last quarter?
Aligos Therapeutics released its earnings results on Nov 06, 2025. The company reported -$3.04 earnings per share for the quarter, missing the consensus estimate of -$1.9 by -$1.14.
Is Aligos Therapeutics overvalued?
According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued.
Does Aligos Therapeutics pay dividends?
Aligos Therapeutics does not currently pay dividends.
What is Aligos Therapeutics’s EPS estimate?
Aligos Therapeutics’s EPS estimate is -2.33.
How many shares outstanding does Aligos Therapeutics have?
Aligos Therapeutics has 5,351,374 shares outstanding.
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Aligos Therapeutics reported an EPS of -$3.04 in its last earnings report, missing expectations of -$1.9. Following the earnings report the stock price went down -3.138%.
Which hedge fund is a major shareholder of Aligos Therapeutics?
Currently, no hedge funds are holding shares in ALGS
Aligos Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$112.50 (1040.97% Upside)
$112.50 (1040.97% Upside)
Hedge Fund Trend
Decreased
By 50.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.55%
12-Months-Change
Fundamentals
Return on Equity
-141.82%
Trailing 12-Months
Asset Growth
23.80%
Trailing 12-Months
Company Description
Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$112.50
▲(1040.97% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―